From Buy To Outperform...Raymond James APTV..140.46 ...Aptiv PLC Company developes software...networking.. and computing platforms geared toward improving vehicle safety and efficiency.. Q1 4 billion Up 20% Year Over Year Earnings Forecast To Grow 72% per year Average Analysts Target Price 200.00 TipRanks Strong Buy Target Price 170.00
Diamond In The Rough..With MAJOR UPSIDE ASTI...02 Ascent Solar Technologies Powerful Comeback Brewing..Tubsolar..Fortsch..Crowdex..Large Orders.. Trading $25 million plus in daily volume ASTI has emerged in recent months as a investors favorite and is currently among the most actively searched and talked about stocks in small caps. Received $2.5 million investment from Bernd Fortsch Via Crowdex and Tubesolar Ag. a well known German Entrepreneur worth millions of Euros. ASTI an early pioneer in Flexible Solar Modules could not be in a stronger position as Solar Energy is currently seeing an enormous Global boost. Great progress was also made in the defense and emergency power market which could add to Revenue growth in 2022 and beyond On March 1st ASTI announced it had been selected by NASA's Space Flight Center in Huntsville, Alabama for participation in two upcoming flight demonstrations On May 17th announce completed delivery of a major contract for its Hyperlight Thin Film Modules..Shipment represented third largest since 2018. The upcoming Lisa-T Demonstration part of NASA's Pathfinder Technology Demonstration 4 Cubeset slated for launch in 2022 will also include ASTI's Photovoltaic Experiment.
From Buy To Outperform TPX..35.69..Tempur Sealy Bedding..Owns Temper-Pedic..Stearns and Foster.. Sealy Brands is leader in Industry Last year shares gained 155% Q1 27% increase year over year Net Cash 15 million to 86 million Return on Equity forecast to be 221% in four years Forecast to grow 16% per year Raymond James Target Price 50.00 TipRanks Strong Buy Target Price 46.00
June Watchlist Despite Some Strong Sell Indicators SIOX..2.19..Sio Gene Therapies Cutting edge science working to develope genetic medicine Gne therapies for Gangliossidosis and Tay-Sachs Disease Unmet clinical needs to potentially treat parkinson's Few weeks ago announced data from study AXO-AAU-GMI an adeno-associated viral vector gene therapy candidate Low Float 31 million TipRanks Strong Buy Target price 7.50
Heavy Insider Buying Last Week MICT..1.81 CEO Bought 6,000,000 shares Earnings Call Monday MICT..Israel-based Company..Developes..manufactures..integrates..and markets rugged computers..tablets and computer-based systems and instruments for the commercial..defense and aerospace markets in US..Israel and Internationally.
Heavy Insider Buying Last Week ELOX..1.55..Elox Pharmaceuticals..Biomedicals-Genetics Insider Buys 15,000,000 shares last week Option Traders could be pricing in a big move..Huge implied volatility could mean a trade on horizon. Also Blackrock owns 1.5 million shares and Vanguard 1.2 million Float Low 25 million TipRanks Moderate Buy Target price 3.50
485,000 Shares bought by Insiders last week PFSI..62.37..PennyMac financial Services..Primarily Mortgage lending Current Housing Boom Blackrock owns 3.7 million shares Vanguard 3.6 million Earnings growth 64% faster than US Industry average of 12% Return on Equity 55% Return on Equity projected to be 21% next three years Stock rose 325% last five years Market Cap 4 Billion Very Low Float 40 Million TipRanks Moderate Buy Target Price 83.20
Keep On Radar IDEX..2.75 Roth Capital Just Raised To Buy With Target Price 7.00 Ideanomics has evolved from a Company expanding an electric car brand to one that's more of a larger holding Company..Has several Brands and Ev-centric products...Wave wireless charging systems for commercial and mass transit fleets.. Beat Earnings last week..Wall Street expecting 11 million..Actual 32 million Grown faster 65% than US Industry average of 31% Forecast to grow 48% per year TipRanks also has 7.00 Target Price
Director of Company Just Bought 664K Shares Worth 19.6 Million CUTR..38.29..Cutera Inc..Medical Devices Executive of a Company is not going to invest that amount of money without feeling confident of growth Blackrock owns 2.7 million shares worth 83 million Considered Undervalued Year Over Year Up 130% Revenue Up 90% year over year Return On Equity forecast to be 30% ,in three years Expanding Footprint In Laser and Energy Based Esthetics..Portfolio Expected To Drive Skincare Revenue Zacks No. 2 Buy TipRanks Moderate Buy Target Price 42.00..But that isn't factoring in Insider Purchase Last Week
Will Insider Buying Indicate Rise GDRX..30.84..GoodRX Last week Insiders bought 375,000Shares valued at 12 million Digital healthcare platform provides prescription drugs at affordable prices Near six month Low Market Cap 12 Billion Low Float 59 Million Strong Institutional Backing Wellington Management Owns 4.5 million shares Morgan Stanley 3.5 million Vanguard 3.2 million TipRanks Moderate Buy Target price 44.18
Upgraded To Buys ITRM..1.14..Iterum Therapeutics Received positive results on Drug treating UTI'S..In Addition Sulopenem likely to be first oral penem class antibiotic to reach market Return On Equity 436% TipRanks Moderate buy Target Price 2.25 MRKR..2.77..Marker Therapeutics Advancing with trial of AML for post-transplant acute myeloid leukemia.. Significantly Undervalued Float 59 million Since Jan.. up 91% Revenue grown faster 116%than US Market average of 17% Revenue forecast to grow 670% per year compared to US biotech average of 51% Oppenheimer Price Target 8.00
Up pre-market 25% SPCE..26.42 Virgin Galactic just launched third successful spaceflight Market Cap 5 Billion TipRanks Moderate Buy Target price 32.89
Pot Stock That Should't Go Up In Smoke CGC..Canopy..22.98 Set growth target of 40-50% over next three years Second largest after Tilray in Canadian Market With product innovation likely to maintain healthy market share Company has strong medicinal cannabis presence in Germany with C3 and wholesale medical sales In US Company looking to expand through CBD-focused Brands Revenue grown faster 184% than Industry Average of 37% Forecast To Grow 51% per year TipRanks Target Price 31.76
Mict..1.81..Up 9% pre-market Earnings Call 8:30 this morning Previously stated CEO bought 6,000,000 Shares last week.
VYST...027 Vystar JUST Announced Posts Highest Revenue and Profit In Company History In First Quarter
UCLE..5186 US Nuclear and Grapheton's New SupercapacitorCould Charge Electric Vehicle In Seconds US Nuclear's partner Grapheton has developed next generation of supercapicitors..Featuring remarkable charge storage capacity and power density..Grapheton's supercapacitors could be used in powering and rapidly charging electric vehicle systems..A typical electric vehicle running on lithium-ion batteries takes about 8 hours to be fully charged.. But Grapheton's supercapacitor system could be fully charged under a minute.
CVAT...061 Cavitation Technologies Announced Purchase Orders for four Nano Reactor Systems in North America. Company anticipates receiving an aggregate revenue of $730,000 for systems.
Goldman Sachs Buy RAIN..16.50..Bio-Pharm Company developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of disease.. Two Drugs In Pipeline. One RAD 52 is a novel approach to the treatment of breast..prostate..pancreatic and ovarian cancers. IPO in April VERY LOW FLOAT 2.19 million Return On Equity Forecast To Be High In 4 Years 192% Goldman Target Price 56.00 Average From Analysts 33.75TipRanks Strong Buy Target Price 33.75
Goldman Sachs Buy RLMD..38.53..Relmade therapeutics Central Nervous System Company's prime pipeline drug candidate NMDA receptor channel blocker under development as a treatment for major depressive disorder VERY LOW FLOAT 11 million Goldman Sachs Price Target 78.00 TipRanks Strong Buy Target Price 67.67
